 Naveen Patil
Concepts (109)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antigens, Viral | 1 | 2021 | 43 | 0.720 |
Why?
| | Resource Allocation | 1 | 2020 | 16 | 0.720 |
Why?
| | Health Resources | 1 | 2020 | 74 | 0.680 |
Why?
| | Pandemics | 3 | 2020 | 564 | 0.660 |
Why?
| | Arkansas | 13 | 2024 | 1991 | 0.560 |
Why?
| | Ticks | 1 | 2016 | 7 | 0.530 |
Why?
| | Tick-Borne Diseases | 1 | 2016 | 5 | 0.530 |
Why?
| | Health Services Accessibility | 1 | 2020 | 420 | 0.530 |
Why?
| | Tuberculosis, Miliary | 1 | 2014 | 4 | 0.480 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 65 | 0.460 |
Why?
| | Tuberculosis | 4 | 2016 | 149 | 0.460 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 108 | 0.450 |
Why?
| | Hepatitis C, Chronic | 1 | 2015 | 86 | 0.450 |
Why?
| | Streptococcus agalactiae | 1 | 2010 | 13 | 0.360 |
Why?
| | Lung | 1 | 2014 | 512 | 0.360 |
Why?
| | Endocarditis, Bacterial | 1 | 2010 | 44 | 0.350 |
Why?
| | Mycobacterium tuberculosis | 3 | 2017 | 287 | 0.340 |
Why?
| | Aortic Valve | 1 | 2010 | 111 | 0.330 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 1160 | 0.320 |
Why?
| | Contact Tracing | 2 | 2020 | 9 | 0.310 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 170 | 0.280 |
Why?
| | Coronavirus Infections | 2 | 2020 | 179 | 0.270 |
Why?
| | Nursing Homes | 3 | 2021 | 113 | 0.250 |
Why?
| | Humans | 20 | 2024 | 50389 | 0.240 |
Why?
| | Malaria, Vivax | 1 | 2024 | 5 | 0.240 |
Why?
| | Antibodies, Viral | 2 | 2021 | 92 | 0.220 |
Why?
| | Mucormycosis | 1 | 2021 | 29 | 0.190 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 2021 | 6 | 0.190 |
Why?
| | Asymptomatic Infections | 1 | 2021 | 5 | 0.190 |
Why?
| | Health Personnel | 2 | 2021 | 252 | 0.180 |
Why?
| | Aged | 8 | 2021 | 9590 | 0.180 |
Why?
| | Convalescence | 1 | 2020 | 6 | 0.180 |
Why?
| | Immunization, Passive | 1 | 2020 | 28 | 0.180 |
Why?
| | Blood Banks | 1 | 2020 | 17 | 0.180 |
Why?
| | Community Health Planning | 1 | 2020 | 27 | 0.180 |
Why?
| | Pneumonia | 1 | 2021 | 118 | 0.180 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2020 | 20 | 0.180 |
Why?
| | Blood Donors | 1 | 2020 | 31 | 0.180 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 30 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 181 | 0.170 |
Why?
| | Prisons | 1 | 2020 | 38 | 0.170 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 578 | 0.160 |
Why?
| | Poverty | 1 | 2020 | 206 | 0.160 |
Why?
| | Sensitivity and Specificity | 1 | 2021 | 875 | 0.150 |
Why?
| | Rural Population | 2 | 2020 | 552 | 0.150 |
Why?
| | Antibiotics, Antitubercular | 1 | 2017 | 17 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 10 | 0.150 |
Why?
| | Sepsis | 1 | 2020 | 227 | 0.150 |
Why?
| | Isoniazid | 1 | 2017 | 36 | 0.150 |
Why?
| | Rifampin | 1 | 2017 | 62 | 0.140 |
Why?
| | Middle Aged | 7 | 2021 | 12460 | 0.140 |
Why?
| | Antitubercular Agents | 1 | 2017 | 106 | 0.140 |
Why?
| | Young Adult | 5 | 2021 | 4064 | 0.140 |
Why?
| | Adolescent | 6 | 2021 | 6475 | 0.140 |
Why?
| | Communicable Diseases, Emerging | 1 | 2016 | 11 | 0.130 |
Why?
| | Leprosy | 1 | 2016 | 6 | 0.130 |
Why?
| | Transients and Migrants | 1 | 2016 | 23 | 0.130 |
Why?
| | Male | 8 | 2021 | 25718 | 0.130 |
Why?
| | Uridine Monophosphate | 1 | 2015 | 4 | 0.120 |
Why?
| | Hepatitis C Antibodies | 1 | 2015 | 20 | 0.120 |
Why?
| | Ribavirin | 1 | 2015 | 15 | 0.120 |
Why?
| | Drug Costs | 1 | 2015 | 39 | 0.120 |
Why?
| | Adult | 7 | 2022 | 13568 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2015 | 168 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 934 | 0.100 |
Why?
| | Prevalence | 3 | 2021 | 970 | 0.100 |
Why?
| | Female | 6 | 2021 | 26981 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1042 | 0.090 |
Why?
| | Neoplasms | 1 | 2020 | 1237 | 0.090 |
Why?
| | Echocardiography, Transesophageal | 1 | 2010 | 61 | 0.090 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 1590 | 0.080 |
Why?
| | Risk Factors | 2 | 2015 | 3692 | 0.080 |
Why?
| | Animals | 2 | 2024 | 13173 | 0.070 |
Why?
| | Plasmodium vivax | 1 | 2024 | 5 | 0.060 |
Why?
| | United States | 3 | 2020 | 4913 | 0.060 |
Why?
| | Travel | 1 | 2024 | 37 | 0.060 |
Why?
| | Gingival Crevicular Fluid | 1 | 2021 | 1 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2021 | 45 | 0.050 |
Why?
| | Antibody Formation | 1 | 2021 | 51 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 62 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2021 | 58 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2021 | 185 | 0.050 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2020 | 12 | 0.050 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1 | 0.040 |
Why?
| | RNA, Viral | 1 | 2021 | 123 | 0.040 |
Why?
| | Housing | 1 | 2021 | 47 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 22 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3180 | 0.040 |
Why?
| | Outpatients | 1 | 2020 | 115 | 0.040 |
Why?
| | Prisoners | 1 | 2021 | 93 | 0.040 |
Why?
| | Child, Preschool | 2 | 2017 | 3908 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 369 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 383 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 231 | 0.030 |
Why?
| | Prospective Studies | 1 | 2021 | 2414 | 0.030 |
Why?
| | Students | 1 | 2017 | 222 | 0.030 |
Why?
| | Child | 2 | 2017 | 6877 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2015 | 174 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2014 | 14 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 170 | 0.030 |
Why?
| | Pilot Projects | 1 | 2016 | 704 | 0.030 |
Why?
| | Urban Population | 1 | 2014 | 152 | 0.030 |
Why?
| | Genotype | 1 | 2014 | 539 | 0.030 |
Why?
| | Sex Factors | 1 | 2014 | 702 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 1017 | 0.020 |
Why?
| | Age Factors | 1 | 2014 | 1104 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6223 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2016 | 2780 | 0.020 |
Why?
| | Infant | 1 | 2016 | 3601 | 0.020 |
Why?
|
|
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|